Posted on 06/04/2010 in Pharmaceutical Company Product News Lilly has received a recommendation from the National Institute for Health and Clinical Excellence (NICE) for Alimta, a chemotherapy treatment for lung cancer patients.
The organisation granted Lilly's treatment a Final Appraisal Determination based on data showing that it can improve overall survival rates for advanced nonsquamous non-small cell lung cancer (NSCLC) sufferers.
This recommendation improves the chances that Alimta will now be approved for NHS funding, having already received European Commission approval in July 2009.
NICE will issue its final guidance on the drug in summer 2010.
John Johnson, president of Lilly Oncology, said: "This decision is a promising step toward recognising the value of Alimta for patients, payer organisations and doctors it means more advanced nonsquamous NSCLC patients may have access to treatment."
Last week, Lilly announced it is extending its clinical trial materials supply chain relationship with Thermo Fisher Scientific in order to improve the efficiency of its development programmes.Other news stories from 06/04/2010
Read more in the Zenopa News Archive
How this news is generated
|
